Immunotherapy with Surgery Raises Hopes for Mesothelioma Patients

An immunotherapy vaccine by itself won't stop malignant pleural mesothelioma, but its ability to enhance the effectiveness of cytoreductive surgery could become the treatment breakthrough that doctors and patients have been seeking for years. The combination of immunotherapy and surgery, which proved especially effective in preclinical research at the University of Pennsylvania, should add to the multimodal treatment approach that includes chemotherapy and radiation for mesothelioma patients. "It is very promising," renowned thoracic surgeon and mesothelioma specialist Dr. Sunil Singhal, of the Abramson Cancer Center, told Asbestos.com. "It's way too early to be sure, but this could become a really big deal." Singhal, who also serves as director of the Thoracic Surgery Research Laboratory at Penn Medicine, believes reducing the mesothelioma tumor burden with surgery gives the immunotherapy vaccine a much better chance of success. "What we've seen so far is that the vaccine by itself — with advanced disease — doesn't seem to work very well," Singhal said. "But if the vaccine can rev up or amplify the immune system, and we take out the tumors, it can attack what's left over and finish the job. There is real potential here." Difficulty Developing the Vaccines Although preclinical research continues to support the development of an immunotherapy approach or helping a patient's own immune system...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Treatment & Doctors Source Type: news

Related Links:

Effects of an ethyl acetate extract of Daphne altaica stem bark on the cell cycle, apoptosis and expression of PPARγ in Eca‑109 human esophageal carcinoma cells. Mol Med Rep. 2020 May 27;: Authors: Kizaibek M, Wubuli A, Gu Z, Bahetjan D, Tursinbai L, Nurhamit K, Chen B, Wang J, Tahan O, Cao P Abstract Daphne altaica Pall. (D. altaica; Thymelaeaceae) has long been used in traditional Kazakh medicine for the treatment of cancer and respiratory diseases. Previous studies have demonstrated the in vitro anticancer effects of D. altaica extract and its constituents in certain cancer ce...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Long non‑coding RNA NNT‑AS1 knockdown represses the progression of gastric cancer via modulating the miR‑142‑5p/SOX4/Wnt/β‑catenin signaling pathway. Mol Med Rep. 2020 May 18;: Authors: Zhang J, Zhang K, Hou Y Abstract Patients with advanced gastric cancer (GC) have a poor prognosis with a median overall survival of 10‑12 months. Long non‑coding RNA nicotinamide nucleotide transhydrogenase‑antisense RNA1 (NNT‑AS1) and sex‑determining region Y‑related high mobility group box 4 (SOX4) have been reported to be associated with the progression of various types of cancer; howe...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
In conclusion, this study developed and validated a prognostic scoring system for alcohol‑related HCC based on lncRNAs. PMID: 32468063 [PubMed - as supplied by publisher]
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Authors: Che J, Wu P, Wang G, Yao X, Zheng J, Guo C Abstract The aim of the present study was to investigate the expression of spalt like transcription factor 4 (SALL4) in the three most common types of renal cell carcinomas (RCC) [clear cell RCC (ccRCC), papillary renal cell carcinoma (pRCC) and chromophobe RCC (chRCC)], and the association with the overall survival (OS) of patients. The Cancer Genome Atlas (TCGA) database and RCC samples were used to investigate the expression levels of the SALL4 gene and its association with the OS in the three types of RCC based on the analysis of the transcriptome, copy number...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Knockdown of ubiquitin‑specific protease 51 attenuates cisplatin resistance in lung cancer through ubiquitination of zinc‑finger E‑box binding homeobox 1. Mol Med Rep. 2020 May 27;: Authors: Zhou F, Du C, Xu D, Lu J, Zhou L, Wu C, Wu B, Huang J Abstract Lung cancer is a devastating cancer with high morbidity and mortality. Ubiquitin‑specific protease (USP) is a type of deubiquitinating enzyme (DUB) that has been implicated in numerous cancers, including colorectal, myeloma and breast. In the present study, the expression of USP51 was determined in the lung cancer cell line A549 and cisplatin (a...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
In conclusion, TCGA classification based on a Chinese population is the same as TCGA typing based on a European population in terms of proportion and clinical characteristics, but there are differences in gene amplification and gene mutation. ACRG molecular classification could be performed by IHC analysis and may be a valuable independent prognostic marker for patients with GC. PMID: 32468041 [PubMed - as supplied by publisher]
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Authors: Hu D, Zhang B, Yu M, Shi W, Zhang L Abstract Colorectal cancer is one of the commoner digestive tract malignant tumor types, and its incidence and mortality rate are high. Accumulating evidence indicates that long‑chain non‑coding RNAs (lncRNAs) and protein‑coding RNAs interact with each other by competing with the same micro(mi)RNA response element (MREs) and serve an important role in the regulation of gene expression in a variety of tumor types. However, the regulatory mechanism and prognostic role of lncRNA‑mediated competing endogenous (ce)RNA networks in colon cancer have yet to be elucidated...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Authors: Zhang S, Yang Y, Hua Y, Hu C, Zhong Y Abstract Colorectal cancer is a digestive tract malignancy and the third leading cause of cancer‑related mortality worldwide. Norcantharidin (NCTD), the demethylated form of cantharidin, has been reported to possess anticancer properties. Family‑with‑sequence‑similarity‑46c (Fam46c), a non‑canonical poly(A) polymerase, has been reported to be critical in NCTD‑mediated effects in numerous types of cancer, including hepatoma. In the current study, it was found that Fam46c expression was reduced in colorectal cancer tissues and cells. Treatment with NCTD was...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Effect of AGER on the biological behavior of non‑small cell lung cancer H1299 cells. Mol Med Rep. 2020 May 22;: Authors: Wang Q, Zhu W, Xiao G, Ding M, Chang J, Liao H Abstract Advanced glycosylation end-product specific receptor (AGER) is a multi-ligand cell surface receptor abnormally expressed in lung cancer, and is a member of the immunoglobulin superfamily. Therefore, this study aimed to explore the effect of AGER on the biological behavior of non‑small cell lung cancer (NSCLC) H1299 cell line. A microarray‑based gene expression profiling analysis of the GSE27262 dataset from the Gene Expres...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Newly diagnosed mesothelioma patients around the world have begun enrolling in a much-anticipated, phase III clinical trial involving an immunotherapy drug combination with groundbreaking potential. The trial, designed as first-line therapy for unresectable pleural mesothelioma, will measure the effectiveness of nivolumab (Opdivo) and ipilimumab (Yervoy) against standard-of-care chemotherapy. A presentation this month at the 2017 American Society of Clinical Oncology (ASCO) annual meeting sparked high expectations for the trial, detailing early, impressive effectiveness involving the two drugs in second-line and third-lin...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Abramson Cancer Center American Society of Clinical Oncology Bristol-Myers Squibb cancer immunotherapy research cisplatin for mesothelioma Cleveland Clinic Cancer Center CRS-207 disease control rate Dr. Arnaud Scherpereel Dr. Patrick Ma Source Type: news
More News: Allergy & Immunology | Asbestosis | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiovascular & Thoracic Surgery | Chemotherapy | Clinical Trials | Environmental Health | Genetics | Immunotherapy | Laboratory Medicine | Listeria | Mesothelioma | Rare Diseases | Skin | University of Pennsylvania | Vaccines | Veterinary Vaccinations